Results of the phase III CARMENA trial show that treatment with sunitinib alone is as good as treatment with nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic renal cell carcinoma.
Results from the JAVELIN Renal 100 study suggest that avelumab plus axitinib is a tolerable combination, with encouraging antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.
In patients with previously untreated metastatic renal cell carcinoma, progression-free survival is significantly longer with the combination of atezolizumab and bevacizumab than with sunitinib, phase III study findings indicate.
Treatment with the multikinase inhibitor cabozantinib is associated with better outcomes than everolimus therapy in patients with previously treated advanced renal cell carcinoma and bone involvement, suggests a prespecified subgroup analysis of the phase III METEOR trial.
Adding immune checkpoint inhibitors to targeted therapy or radiotherapy can worsen some of the toxic effects associated with these treatment modalities, indicate two reports published in JAMA Oncology.
Phase III trial results presented at the ESMO 2017 Congress support the use of nivolumab plus ipilimumab for the first-line treatment of patients with advanced or metastatic clear-cell renal cell carcinoma.
This report provides an overview of three studies investigating the combination of immunotherapy with targeted agents in treatment-naïve patients with locally advanced or metastatic renal cell carcinoma.
Adjuvant treatment with sunitinib or sorafenib does not prolong disease-free survival or overall survival in clear cell renal cell carcinoma patients classed as high risk, shows a post hoc analysis of the placebo-controlled ASSURE trial.
Cabozantinib significantly improves progression-free survival in newly diagnosed patients with intermediate- or poor-risk metastatic renal cell carcinoma, shows a head-to-head comparison with the standard of care sunitinib.
Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus.